FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:518-520 February 2, 2006 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Grass, G. Related Article by Honer, W. G. PubMed Citation

Schizophrenia is a serious chronic illness that requires lifelong medication. In some patients, the illness is refractory to even highly effective medications such as clozapine, and these patients desperately need more effective treatment regimens. Less dopamine is blocked with clozapine than with other antipsychotic medications, and adding more potent dopamine-blocking drugs, such as risperidone, to clozapine may achieve better efficacy. Three randomized, controlled trials examined the strategy of adding risperidone to clozapine for patients whose illness is refractory to treatment with clozapine alone. In this issue of the Journal, Honer et al.¹ report the results of a trial supported by . . . [Full Text of this Article]

Source Information

From the Psychiatric Institute, University of Illinois at Chicago, Chicago, and the University of Maryland Psychiatric Research Center, Baltimore.

This article has been cited by other articles:

• Rosenheck, R. A. (2007). Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br. J. Psychiatry 191: 238-245 [Abstract] [Full Text]  
• Freedman, R., Carpenter, W. T. JR., Davis, J. M., Goldman, H. H., Tamminga, C. A., Thomas, M. (2006). The Costs of Drugs for Schizophrenia. Am. J. Psychiatry 163: 2029-2031 [Full Text]  
• Lehman, R. (2006). Evidently.... Evid. Based Med. 11: 71-71 [Full Text]  
• Grass, G., Hellmich, M., Leweke, F. M., Meltzer, H. Y., Yagcioglu, A. E. A., Akdede, B. B. K., Gerson, S. L., Honer, W. G., Thornton, A. E., MacEwan, G. W., Davis, J. M. (2006). Clozapine alone versus clozapine and risperidone for refractory schizophrenia.. NEJM 354: 1846-1848 [Full Text]